A pharmaceutical preparation of rn-509, which can be used in mammals, especially in people with diseases or diseases related to Androgene (male) receptor,Especially cancer, especially prostate cancer, including prostate cancer without fluoroscopy, prostate cancer without fluoroscopy, prostate cancer without fluoroscopy, and prostate cancer with castration resistance and metastasis without chemical treatment, Prostate cancer sensitive to biochemical hormones or resistant to castration and at high risk of non metabolic prostate cancer. On one hand, these formulations include rn-509 strong scattering and acrylic copolymers. In one wayThe solid dispersion of rn-509 and acrylic copolymer (MET) can be achieved by fusing a mixture including rn-509 and acrylic copolymer (MET), but also by subsequent melting. Rn-509 and an acrylic acid copolymer (MET) can be obtained, in particular,Dehydration is carried out with an appropriate solvent by spraying a mixture including rn-509 and an acrylic police complex (MET). 11. Claim 11: a particle consisting of solid scattering as defined in any one of claims 1 to 9.Formulaciones farmacéuticas de ARN-509 que pueden ser administradas a un mamífero, particularmente a un ser humano, que padece de una enfermedad o afección relacionada con el receptor androgénico (RA), particularmente cáncer, más particularmente cáncer de próstata, incluidos, a titulo meramente enunciativo, cáncer de próstata resistente a la castración, cáncer de próstata con metástasis resistente a la castración, cáncer de próstata con metástasis resistente a la castración sin tratamiento previo con quimioterapia, cáncer de próstata sensible a las hormonas con recidiva bioquímica o cáncer de próstata no metastásico resistente a la castración y de alto riesgo. En un aspecto, estas formulaciones comprenden una dispersión sólida de ARN-509 y un copolímero de poli(met)acrilato. En un aspecto, la dispersión sólida de ARN-509 y un copolímero de poli(met)acrilato se puede obtener,
